GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Processa Pharmaceuticals Inc (NAS:PCSA) » Definitions » E10

PCSA (Processa Pharmaceuticals) E10 : $-108.48 (As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Processa Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Processa Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2024 was $-1.030. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-108.48 for the trailing ten years ended in Sep. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2025-03-14), Processa Pharmaceuticals's current stock price is $0.4467. Processa Pharmaceuticals's E10 for the quarter that ended in Sep. 2024 was $-108.48. Processa Pharmaceuticals's Shiller PE Ratio of today is .


Processa Pharmaceuticals E10 Historical Data

The historical data trend for Processa Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Processa Pharmaceuticals E10 Chart

Processa Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -228.44 -200.83 -154.59

Processa Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -164.63 -154.59 -134.93 -121.26 -108.48

Competitive Comparison of Processa Pharmaceuticals's E10

For the Biotechnology subindustry, Processa Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Processa Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Processa Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Processa Pharmaceuticals's Shiller PE Ratio falls into.



Processa Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Processa Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-1.03/133.0289*133.0289
=-1.030

Current CPI (Sep. 2024) = 133.0289.

Processa Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201412 -303.801 99.070 -407.938
201503 -58.800 99.621 -78.518
201506 -186.200 100.684 -246.017
201509 -29.400 100.392 -38.958
201512 -39.200 99.792 -52.256
201603 -9.800 100.470 -12.976
201606 -9.800 101.688 -12.820
201609 -9.800 101.861 -12.799
201612 0.000 101.863 0.000
201703 -9.800 102.862 -12.674
201706 -4.764 103.349 -6.132
201709 -19.600 104.136 -25.038
201712 -6.086 104.011 -7.784
201803 -4.200 105.290 -5.307
201806 -4.200 106.317 -5.255
201809 -2.800 106.507 -3.497
201812 -1.600 105.998 -2.008
201903 -2.800 107.251 -3.473
201906 -3.600 108.070 -4.431
201909 -3.200 108.329 -3.930
201912 -4.600 108.420 -5.644
202003 -3.200 108.902 -3.909
202006 -2.600 108.767 -3.180
202009 -11.000 109.815 -13.325
202012 -20.243 109.897 -24.504
202103 -2.800 111.754 -3.333
202106 -4.000 114.631 -4.642
202109 -3.800 115.734 -4.368
202112 -4.200 117.630 -4.750
202203 -4.000 121.301 -4.387
202206 -6.400 125.017 -6.810
202209 -7.400 125.227 -7.861
202212 -16.050 125.222 -17.051
202303 -3.530 127.348 -3.687
202306 -1.940 128.729 -2.005
202309 -1.540 129.860 -1.578
202312 -1.670 129.419 -1.717
202403 -1.110 131.776 -1.121
202406 -1.010 132.554 -1.014
202409 -1.030 133.029 -1.030

Add all the adjusted EPS together and divide 10 will get our e10.


Processa Pharmaceuticals  (NAS:PCSA) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Processa Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Processa Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Processa Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
7380 Coca Cola Drive, Suite 106, Hanover, MD, USA, 21076
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
Executives
George K Ng officer: Chief Executive Officer C/O SORRENTO THERAPEUTICS, INC., 6042 CORNERSTONE COURT WEST, SUITE B, SAN DIEGO CA 92121
Justin W Yorke director C/O JMG EXPLORATION, 180 SOUTH LAKE AVENUE, PASADENA CA 91101
David Young director, 10 percent owner, officer: President & CEO 8850 STANFORD BOULEVARD, SUITE 2500, COLUMBIA MD 21045
Patrick Lin officer: Chief Business - Strategy Off 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
Wendy Guy officer: Chief Administrative Officer 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
James H Stanker officer: Chief Financial Officer 9008 SHADYBROOK DRIVE, FREDERICK MD 21701
Khoso Baluch director 1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921
James R Neal director 2910 SEVENTH STREET, BERKELEY CA 94710
Virgil Thompson director 319 SOUTH NARDO, SOIANA BEACH CA 92075
Geraldine Pannu director 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
Robert Michael Floyd officer: Chief Operating Officer C/O PROCESSA PHARMACEUTICALS, INC., 7300 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
James E Besser 10 percent owner 3 WEST HILL PLACE, BOSTON MA 02114
Khalid Islam director C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Sian Bigora officer: Chief Development Officer 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076